These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 10356119)
1. Using pathophysiology in acute stroke trials. Baird AE; Warach S Stroke; 1999 Jun; 30(6):1293. PubMed ID: 10356119 [No Abstract] [Full Text] [Related]
2. Neuroprotective therapy in acute ischemic stroke. Thurston SE Va Med Q; 1998; 125(2):131-2. PubMed ID: 9577717 [No Abstract] [Full Text] [Related]
3. A review of earlier clinical studies on neuroprotective agents and current approaches. Wahlgren NG Int Rev Neurobiol; 1997; 40():337-63. PubMed ID: 8989628 [No Abstract] [Full Text] [Related]
5. Neuroprotective and thrombolytic agents: advances in stroke treatment. Hock N J Neurosci Nurs; 1998 Jun; 30(3):175-84. PubMed ID: 9689609 [TBL] [Abstract][Full Text] [Related]
6. Considerations in the design of clinical trials of neuroprotective therapy in acute stroke. Dorman PJ; Sandercock PA Stroke; 1996 Sep; 27(9):1507-15. PubMed ID: 8784121 [TBL] [Abstract][Full Text] [Related]
7. Finding new drugs to treat stroke. Barinaga M Science; 1996 May; 272(5262):664-6. PubMed ID: 8614822 [No Abstract] [Full Text] [Related]
9. The role of glutamic acid in the pathogenesis of stroke and the development of neuroprotective drugs. Evans SM; Addae JI West Indian Med J; 1995 Dec; 44(4):119-23. PubMed ID: 8838047 [TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled ascending dose tolerance study of 619C89 in acute stroke. Muir KW; Lees KR; Hamilton SJ; George CF; Hobbiger SF; Lunnon MW Ann N Y Acad Sci; 1995 Sep; 765():328-9. PubMed ID: 7486634 [No Abstract] [Full Text] [Related]
11. Effectively bridging the preclinical/clinical gap: the results of the ASTIN trial. Sughrue ME; Connolly ES Stroke; 2004 Apr; 35(4):e81-2; author reply e81-2. PubMed ID: 14988564 [No Abstract] [Full Text] [Related]
15. Neuroprotective actions of thyroid hormones and low-T3 syndrome as a biomarker in acute cerebrovascular disorders. Bunevicius A; Iervasi G; Bunevicius R Expert Rev Neurother; 2015 Mar; 15(3):315-26. PubMed ID: 25673072 [TBL] [Abstract][Full Text] [Related]
16. [Effect of cavinton on the hemorheological parameters of chronic cerebrovascular patients]. Sapary L; Horvath B; Alexy T; Marton Z; Kesmarky G; Zsots M; Nagy F; Czopf I; Toth K Zh Nevrol Psikhiatr Im S S Korsakova; 2006; 106(6):47-51. PubMed ID: 16841484 [No Abstract] [Full Text] [Related]
17. Brain protection--human data and potential new therapies. Morgenstern LB; Pettigrew LC New Horiz; 1997 Nov; 5(4):397-405. PubMed ID: 9433992 [TBL] [Abstract][Full Text] [Related]
18. [The role of vinpocetine in the treatment of cerebrovascular diseases based in human studies]. Bagoly E; Fehér G; Szapáry L Orv Hetil; 2007 Jul; 148(29):1353-8. PubMed ID: 17631470 [TBL] [Abstract][Full Text] [Related]
19. Controlled clinical trials in stroke. Fieschi C; Frontoni M; Argentino C; Orzi F; Toni D; Millefiorini E; Carolei A; Cavalletti C Arzneimittelforschung; 1991 Mar; 41(3A):344-7. PubMed ID: 1859506 [TBL] [Abstract][Full Text] [Related]